QIAGEN/$QGEN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About QIAGEN
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
Ticker
$QGEN
Sector
Primary listing
NYSE
Employees
5,700
Headquarters
Website
QIAGEN Metrics
BasicAdvanced
$10B
28.21
$1.69
0.64
$0.25
0.52%
Price and volume
Market cap
$10B
Beta
0.64
52-week high
$51.88
52-week low
$37.63
Average daily volume
1.3M
Dividend rate
$0.25
Financial strength
Current ratio
1.612
Quick ratio
1.187
Long term debt to equity
25.242
Total debt to equity
41.194
Interest coverage (TTM)
22.13%
Profitability
EBITDA (TTM)
1,006.337
Gross margin (TTM)
80.68%
Net profit margin (TTM)
18.30%
Operating margin (TTM)
40.28%
Effective tax rate (TTM)
23.59%
Revenue per employee (TTM)
$360,000
Management effectiveness
Return on assets (TTM)
9.10%
Return on equity (TTM)
10.81%
Valuation
Price to earnings (TTM)
28.208
Price to revenue (TTM)
5.077
Price to book
2.95
Price to tangible book (TTM)
16.2
Price to free cash flow (TTM)
20.962
Free cash flow yield (TTM)
4.77%
Free cash flow per share (TTM)
2.278
Dividend yield (TTM)
0.52%
Forward dividend yield
0.52%
Growth
Revenue change (TTM)
5.15%
Earnings per share change (TTM)
405.09%
3-year revenue growth (CAGR)
-3.37%
10-year revenue growth (CAGR)
4.49%
3-year earnings per share growth (CAGR)
-11.72%
10-year earnings per share growth (CAGR)
13.31%
Bulls say / Bears say
Qiagen raised its full-year 2025 adjusted EPS outlook to approximately $2.35 from $2.28 and reported preliminary Q1 net sales of $483 million at constant exchange rates (up 7% YoY), surpassing the Bloomberg consensus estimate and underscoring strong early-year demand (Reuters)
In Q2 2025, Qiagen delivered net sales of $534 million, a 7% year-over-year increase that beat its guidance and prompted management to raise the full-year net sales growth outlook to 4–5% at constant exchange rates (RTTNews)
Adjusted operating income margin expanded to 29.9% in Q2 2025 from 28.4% a year earlier, driven by disciplined cost management and efficiency programs, positioning the company to reach its 31% margin target ahead of schedule (Business Wire)
Sales in the Asia-Pacific region declined 4% at constant exchange rates in Q2 2025, highlighting persistent headwinds in key emerging markets that may weigh on overall growth prospects (TipRanks)
Sample technologies sales were broadly flat year-over-year in Q2 2025, suggesting saturation in core consumables amid constrained R&D budgets and limited capital spending in life sciences research (TipRanks)
Analysts maintain a consensus “Hold” rating on QGEN with an average price target of $49.69—only about 11% above current levels—indicating modest conviction in the stock’s near-term upside (MarketBeat)
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.
QIAGEN News
AllArticlesVideos
QIAGEN Secures European CE-IVDR Certification for Full QIAstat-Dx Portfolio
Business Wire4 weeks ago
QIAGEN Gains U.S. Clearance of Higher-Throughput QIAstat-Dx Rise, Expanding Patient Access to Rapid Syndromic Testing
Business Wire1 month ago
QIAGEN N.V. Announces Conversion Price of New Net Share Settled Convertible Bonds
Business Wire1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for QIAGEN stock?
QIAGEN (QGEN) has a market cap of $10B as of October 09, 2025.
What is the P/E ratio for QIAGEN stock?
The price to earnings (P/E) ratio for QIAGEN (QGEN) stock is 28.21 as of October 09, 2025.
Does QIAGEN stock pay dividends?
Yes, the QIAGEN (QGEN) stock pays dividends to shareholders. As of October 09, 2025, the dividend rate is $0.25 and the yield is 0.52%. QIAGEN has a payout ratio of 0% on a trailing twelve-month basis.
When is the next QIAGEN dividend payment date?
The next QIAGEN (QGEN) dividend payment date is unconfirmed.
What is the beta indicator for QIAGEN?
QIAGEN (QGEN) has a beta rating of 0.64. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.